RedHill Biopharma (RDHL) Income towards Parent Company (2016 - 2023)
Historic Income towards Parent Company for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $58.9 million.
- RedHill Biopharma's Income towards Parent Company rose 79179.66% to $58.9 million in Q2 2023 from the same period last year, while for Dec 2024 it was $58.9 million, marking a year-over-year increase of 41816.51%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 6110142821.12% down from last year.
- As of Q2 2023, RedHill Biopharma's Income towards Parent Company stood at $58.9 million, which was up 79179.66% from -$7.9 million recorded in Q1 2023.
- RedHill Biopharma's Income towards Parent Company's 5-year high stood at $58.9 million during Q2 2023, with a 5-year trough of -$145.2 million in Q4 2021.
- Its 5-year average for Income towards Parent Company is -$1.3 million, with a median of $11.1 million in 2019.
- Per our database at Business Quant, RedHill Biopharma's Income towards Parent Company crashed by 106284.39% in 2021 and then soared by 79179.66% in 2023.
- RedHill Biopharma's Income towards Parent Company (Quarter) stood at $11.8 million in 2019, then increased by 27.44% to $15.1 million in 2020, then crashed by 1062.84% to -$145.2 million in 2021, then soared by 52.14% to -$69.5 million in 2022, then soared by 184.75% to $58.9 million in 2023.
- Its Income towards Parent Company stands at $58.9 million for Q2 2023, versus -$7.9 million for Q1 2023 and -$69.5 million for Q4 2022.